Percutaneous left atrial appendage closure: procedural techniques and outcomes.

Area of Science:

• Cardiology
• Medical Devices
• Stroke Prevention

Background:

• Percutaneous left atrial appendage closure (LAAC) technology has advanced significantly for stroke prevention in atrial fibrillation (AF) patients.
• Several LAAC devices are under clinical investigation, with some already CE-marked and available globally.
• The WATCHMAN device has substantial data and is under FDA evaluation for warfarin-eligible patients.

Purpose of the Study:

• To review procedural techniques, safety, and outcomes of leading percutaneous left atrial appendage closure devices.
• To provide an in-depth analysis of current LAAC technologies for stroke prevention in AF.
• To discuss the evolving landscape of LAAC, including upcoming trials and FDA approvals.

Main Methods:

• Review of clinical investigation data for leading LAAC devices.
• Analysis of real-world experience with devices like the Amplatzer Cardiac Plug.
• Evaluation of safety and efficacy data, including adverse event rates for devices like the Lariat procedure.

Main Results:

• The WATCHMAN device has the most supportive data for FDA evaluation.
• The Amplatzer Cardiac Plug has extensive real-world experience, with a comparative trial anticipated.
• Early studies on the Lariat procedure showed concerning rates of pericardial effusion and bleeding.

Conclusions:

• LAAC technology is rapidly evolving, offering new stroke prevention options for AF patients.
• Current practice primarily involves patients unsuitable for long-term anticoagulation, but this is expected to change with wider FDA approvals.
• This review provides comprehensive insights into the leading LAAC devices, their application, and clinical performance.